<DOC>
	<DOCNO>NCT01883219</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tyrosine kinase inhibitor ( TKI ) therapy base molecular monitoring BCR/ABL level Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph+ ALL ) undergo allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) .</brief_summary>
	<brief_title>TKI Therapy Based Molecular Monitoring Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Philadelphia chromosome ( Ph ) reciprocal chromosomal translocation ( 9 ; 22ï¼‰ ( q34 ; q11 ) , lead formation BCR/ABL oncogene . Ph frequent cytogenetic abnormality ALL characterize poor outcome . With BCR/ABL protein TKI , imatinib , combination chemotherapy regimes newly diagnose Ph+ ALL , 95 % patient achieve complete remission ( CR ) 1 . Several study show decreased relapse rate improve disease-free survival patient imatinib-based treatment prior allo-HSCT . However , efficacy maintenance therapy imatinib transplant Ph+ ALL patient still uncertain . In addition , acquire resistance imatinib frequently cause point mutation BCR/ABL inactivate imatinib . Detection minimal residual disease ( MRD ) transplant associate increase risk relapse . Reverse transcription-polymerase chain reaction ( RT-PCR ) sensitive method detect low-level BCR/ABL transcript assess MRD Ph+ ALL . It corroborate several report detection MRD SCT predictive imminent relapse . In study , evaluate safety efficacy TKI therapy , initiate treatment base BCR-ABL transcript level allo-HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>A patient age 1465 year AlloHSCT recipient ph+ ALL Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) patient hematological relapse , extramedullary involvement leukemia Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Allogeneic hematopoietic cell transplantation</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>